RU2008108219A - Соединения, представляющие собой 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенный пиридин, для лечения неврологических, психиатрических или болевыхрасстройств - Google Patents
Соединения, представляющие собой 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенный пиридин, для лечения неврологических, психиатрических или болевыхрасстройств Download PDFInfo
- Publication number
- RU2008108219A RU2008108219A RU2008108219/04A RU2008108219A RU2008108219A RU 2008108219 A RU2008108219 A RU 2008108219A RU 2008108219/04 A RU2008108219/04 A RU 2008108219/04A RU 2008108219 A RU2008108219 A RU 2008108219A RU 2008108219 A RU2008108219 A RU 2008108219A
- Authority
- RU
- Russia
- Prior art keywords
- disorder
- pain
- compound according
- clause
- disorders
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 47
- 150000001875 compounds Chemical class 0.000 title claims abstract 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title claims abstract 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title claims abstract 5
- 201000010099 disease Diseases 0.000 title claims 3
- 230000000926 neurological effect Effects 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 10
- 102000001708 Protein Isoforms Human genes 0.000 claims abstract 6
- 108010029485 Protein Isoforms Proteins 0.000 claims abstract 6
- 150000004677 hydrates Chemical class 0.000 claims abstract 6
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims abstract 5
- 208000012902 Nervous system disease Diseases 0.000 claims abstract 3
- 230000001404 mediated effect Effects 0.000 claims abstract 3
- 208000020016 psychiatric disease Diseases 0.000 claims abstract 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims abstract 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims abstract 2
- -1 5 - {(1R) -1- [5- (3-chlorophenyl) isoxazol-3-yl] ethoxy} -4-methyl-4H-1,2,4-triazole- hydrochloride Chemical compound 0.000 claims abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract 2
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims abstract 2
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 208000010643 digestive system disease Diseases 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims abstract 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims abstract 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 230000003287 optical effect Effects 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims abstract 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims abstract 2
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 2
- 208000035475 disorder Diseases 0.000 claims 39
- 238000000034 method Methods 0.000 claims 14
- 208000019695 Migraine disease Diseases 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 8
- 206010027599 migraine Diseases 0.000 claims 8
- 208000027520 Somatoform disease Diseases 0.000 claims 6
- 208000027753 pain disease Diseases 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 230000036506 anxiety Effects 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 206010011224 Cough Diseases 0.000 claims 4
- 206010065390 Inflammatory pain Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 206010015037 epilepsy Diseases 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 2
- 206010004663 Biliary colic Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 206010019196 Head injury Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000013016 Hypoglycemia Diseases 0.000 claims 2
- 208000036626 Mental retardation Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 206010038419 Renal colic Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 208000009205 Tinnitus Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 235000019788 craving Nutrition 0.000 claims 2
- 201000006549 dyspepsia Diseases 0.000 claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 208000037906 ischaemic injury Diseases 0.000 claims 2
- 230000005906 menstruation Effects 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 230000002981 neuropathic effect Effects 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 231100000886 tinnitus Toxicity 0.000 claims 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 210000001766 X chromosome Anatomy 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72152705P | 2005-09-29 | 2005-09-29 | |
| US60/721,527 | 2005-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008108219A true RU2008108219A (ru) | 2009-11-10 |
Family
ID=37745801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008108219/04A RU2008108219A (ru) | 2005-09-29 | 2006-09-20 | Соединения, представляющие собой 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенный пиридин, для лечения неврологических, психиатрических или болевыхрасстройств |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20080227824A1 (enExample) |
| EP (1) | EP1934209A1 (enExample) |
| JP (2) | JP2009510064A (enExample) |
| KR (1) | KR20080050421A (enExample) |
| CN (1) | CN101273037A (enExample) |
| AR (1) | AR058807A1 (enExample) |
| AU (1) | AU2006297462A1 (enExample) |
| BR (1) | BRPI0616228A2 (enExample) |
| CA (1) | CA2623009A1 (enExample) |
| EC (1) | ECSP088283A (enExample) |
| IL (1) | IL189990A0 (enExample) |
| NO (1) | NO20081434L (enExample) |
| RU (1) | RU2008108219A (enExample) |
| TW (1) | TW200800976A (enExample) |
| UA (1) | UA92503C2 (enExample) |
| UY (1) | UY29796A1 (enExample) |
| WO (1) | WO2007040982A1 (enExample) |
| ZA (1) | ZA200802163B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR040847A1 (es) * | 2002-08-09 | 2005-04-20 | Astrazeneca Ab | 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| AR058807A1 (es) * | 2005-09-29 | 2008-02-27 | Astrazeneca Ab | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 |
| TW200821305A (en) * | 2006-10-05 | 2008-05-16 | Astrazeneca Ab | MGluR5 modulators |
| UY31403A1 (es) | 2007-10-19 | 2009-05-29 | "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos". | |
| JP2011500798A (ja) * | 2007-10-26 | 2011-01-06 | アストラゼネカ・アクチエボラーグ | ｍＧｌｕＲ５のモジュレーターとしてのアミノ１，２，４−トリアゾール誘導体 |
| RU2011103225A (ru) * | 2008-08-12 | 2012-09-20 | Астразенека Аб (Se) | Новая кристаллическая форма 4-(5-{(1r)-1-[5-(3-хрорфенил)изоксазол-3-ил]этокси}-4-метил-4h-1,2,4-триазол-3-ил)пиридина |
| BRPI0917465A2 (pt) * | 2008-08-12 | 2017-04-04 | Astrazeneca Ab | composto, formulação farmacêutica, uso de um composto, método para tratamento ou prevenção de um distúrbio, e, processo para preparar um composto |
| AU2009307825A1 (en) * | 2008-10-22 | 2010-04-29 | Rick FRIEDMAN | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
| SG171743A1 (en) * | 2008-12-12 | 2011-07-28 | Astrazeneca Ab | A new process for preparing 4- [4-methyl-5- (cl- 10alkylthio/c5-10aryl-cl-6alkylthio) -4h-1, 2, 4-triazol-3- yl] pyridines |
| KR20110101164A (ko) * | 2008-12-18 | 2011-09-15 | 아스트라제네카 아베 | 1-〔5-(3-클로로-페닐)-이소옥사졸-3-일〕-에타논 및 (ｒ)-1-〔5-(3-클로로-페닐)-이속사졸-3-일〕-에탄올의 신규 제조 방법 |
| WO2010071559A1 (en) * | 2008-12-18 | 2010-06-24 | Astrazeneca Ab | Processes for the manufacture of 3-{4-methyl-5- [ (ir) -1- (2- (3-methylphenyl) -2h-tetrazol-5-yl) -ethoxy] -4h- [1,2, 4] triazol-3-yl} -pyridine, 4-methyl-3-methylthio-5- (3- pyridyl)-l,2,4-triazole, and (ir) -1- [2- (3-methylphenyl) -2h- tetrazol-5-yl] ethanol |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| AU2010255552A1 (en) * | 2009-06-05 | 2012-01-12 | Oslo University Hospital Hf | Azole derivatives as Wtn pathway inhibitors |
| WO2011082010A1 (en) | 2009-12-29 | 2011-07-07 | Eli Lilly And Company | Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
| ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
| US8080568B1 (en) * | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| UA112418C2 (uk) | 2010-09-07 | 2016-09-12 | Астеллас Фарма Інк. | Терапевтичний болезаспокійливий засіб |
| WO2012076898A1 (en) | 2010-12-08 | 2012-06-14 | Oslo University Hospital Hf | Triazole derivatives as wnt signaling pathway inhibitors |
| US20140228398A1 (en) | 2011-03-18 | 2014-08-14 | Novartis Ag | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE |
| KR20160120157A (ko) | 2015-04-07 | 2016-10-17 | 주식회사 메드팩토 | 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법 |
| WO2016163754A1 (en) * | 2015-04-07 | 2016-10-13 | Medpacto Inc. | Pharmaceutical composition for preventing or treating cancer and method using thereof |
| KR102027368B1 (ko) * | 2018-05-29 | 2019-10-01 | 서울대학교산학협력단 | 통증의 강도를 측정하는 방법 |
| CN113329754A (zh) | 2018-11-20 | 2021-08-31 | 麻雀制药股份有限公司 | 用于施用皮质类固醇的方法 |
| BR112021019911A2 (pt) * | 2019-05-15 | 2021-12-07 | Claes Thulin | 4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1,2,4-triazol-3-il]piridina para uso na prevenção e/ou no tratamento da dor em um animal |
| US20220387410A1 (en) * | 2019-11-05 | 2022-12-08 | Claes Thulin | 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal |
| AU2023273030A1 (en) | 2022-05-16 | 2024-11-07 | Sparrow Pharmaceuticals, Inc. | Methods and compositions for treating glucocorticoid excess |
| US20260124188A1 (en) | 2022-10-28 | 2026-05-07 | Orphelion Ab | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1313465C (zh) | 1999-08-19 | 2007-05-02 | Nps药物有限公司 | 杂多环化合物及其用于制备代谢性谷氨酸受体拮抗剂的应用 |
| CA2438991C (en) * | 2001-02-21 | 2010-08-17 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| WO2004014902A2 (en) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| TW200424183A (en) | 2002-08-09 | 2004-11-16 | Nps Pharma Inc | New compounds |
| AR040847A1 (es) | 2002-08-09 | 2005-04-20 | Astrazeneca Ab | 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos |
| WO2005060971A1 (en) * | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of reflux-related diseases |
| CA2548039A1 (en) | 2003-12-19 | 2005-07-21 | Astrazenca Ab | 5-fluoro-, chloro- and cyano-pyridin-2-yl-tetrazoles as ligands of the metabotropic glutamate receptor-5 |
| WO2005077345A1 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| WO2005077368A2 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| EP1716130A1 (en) | 2004-02-18 | 2006-11-02 | AstraZeneca AB | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists |
| US20070185095A1 (en) | 2004-02-18 | 2007-08-09 | Astrazeneca Ab | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| AU2005214378A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| CN101845023A (zh) | 2004-02-18 | 2010-09-29 | 阿斯利康(瑞典)有限公司 | 四唑化合物及其作为代谢型谷氨酸受体拮抗剂的应用 |
| EP1720860A1 (en) | 2004-02-18 | 2006-11-15 | AstraZeneca AB | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
| AR058807A1 (es) * | 2005-09-29 | 2008-02-27 | Astrazeneca Ab | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 |
-
2006
- 2006-09-15 AR ARP060104038A patent/AR058807A1/es not_active Application Discontinuation
- 2006-09-15 UY UY29796A patent/UY29796A1/es not_active Application Discontinuation
- 2006-09-19 TW TW095134584A patent/TW200800976A/zh unknown
- 2006-09-20 WO PCT/US2006/036423 patent/WO2007040982A1/en not_active Ceased
- 2006-09-20 US US12/067,270 patent/US20080227824A1/en not_active Abandoned
- 2006-09-20 CA CA002623009A patent/CA2623009A1/en not_active Abandoned
- 2006-09-20 BR BRPI0616228-2A patent/BRPI0616228A2/pt not_active IP Right Cessation
- 2006-09-20 US US11/523,717 patent/US7476684B2/en not_active Expired - Fee Related
- 2006-09-20 UA UAA200802884A patent/UA92503C2/ru unknown
- 2006-09-20 CN CNA2006800343984A patent/CN101273037A/zh active Pending
- 2006-09-20 AU AU2006297462A patent/AU2006297462A1/en not_active Abandoned
- 2006-09-20 KR KR1020087006537A patent/KR20080050421A/ko not_active Withdrawn
- 2006-09-20 RU RU2008108219/04A patent/RU2008108219A/ru not_active Application Discontinuation
- 2006-09-20 JP JP2008533434A patent/JP2009510064A/ja active Pending
- 2006-09-20 EP EP06803836A patent/EP1934209A1/en not_active Withdrawn
-
2007
- 2007-07-27 US US11/829,866 patent/US20070270468A1/en not_active Abandoned
- 2007-07-27 US US11/829,867 patent/US20070270469A1/en not_active Abandoned
-
2008
- 2008-03-06 IL IL189990A patent/IL189990A0/en unknown
- 2008-03-07 ZA ZA200802163A patent/ZA200802163B/xx unknown
- 2008-03-14 EC EC2008008283A patent/ECSP088283A/es unknown
- 2008-03-19 NO NO20081434A patent/NO20081434L/no not_active Application Discontinuation
-
2009
- 2009-09-14 JP JP2009211258A patent/JP2010013476A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20070129408A1 (en) | 2007-06-07 |
| BRPI0616228A2 (pt) | 2011-06-14 |
| CN101273037A (zh) | 2008-09-24 |
| NO20081434L (no) | 2008-05-19 |
| UY29796A1 (es) | 2007-04-30 |
| ZA200802163B (en) | 2009-09-30 |
| US20070270468A1 (en) | 2007-11-22 |
| AR058807A1 (es) | 2008-02-27 |
| WO2007040982A1 (en) | 2007-04-12 |
| IL189990A0 (en) | 2008-08-07 |
| TW200800976A (en) | 2008-01-01 |
| CA2623009A1 (en) | 2007-04-12 |
| KR20080050421A (ko) | 2008-06-05 |
| JP2010013476A (ja) | 2010-01-21 |
| US20080227824A1 (en) | 2008-09-18 |
| US20070270469A1 (en) | 2007-11-22 |
| EP1934209A1 (en) | 2008-06-25 |
| UA92503C2 (ru) | 2010-11-10 |
| ECSP088283A (es) | 2008-04-28 |
| JP2009510064A (ja) | 2009-03-12 |
| US7476684B2 (en) | 2009-01-13 |
| AU2006297462A1 (en) | 2007-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006128446A (ru) | Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора | |
| JP2009510064A5 (enExample) | ||
| JP2007523168A5 (enExample) | ||
| JP5749802B2 (ja) | 非定型抗精神病薬及びｔａａｒ１アゴニストを含む組合せ | |
| JP2011500673A5 (enExample) | ||
| JP2005527593A5 (enExample) | ||
| JP2008513516A5 (enExample) | ||
| ME01488B (me) | Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842 | |
| TWI439451B (zh) | 雜環胺衍生物 | |
| AR059206A1 (es) | Uso de derivados de 4-imidazol para trastornos del snc | |
| JP2010526145A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| CN103502227A (zh) | 作为bace1和／或bace2抑制剂的1,3噁嗪类 | |
| RU2009136592A (ru) | Терапевтические агенты | |
| JP2017533968A5 (enExample) | ||
| NZ586301A (en) | Benzothiazole and benzoxazole derivatives and methods of use | |
| JP2008508247A5 (enExample) | ||
| MA35062B1 (fr) | Dérivés d'amines hétérocycliques | |
| CA2570197A1 (en) | Nk1 antagonists | |
| JP2019512533A5 (enExample) | ||
| US10647679B2 (en) | N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto | |
| JP2012528824A5 (enExample) | ||
| US8673950B2 (en) | Dihydrooxazol-2-amine derivatives | |
| RU2443697C1 (ru) | Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения | |
| JP2010514682A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20120111 |